Commentary: Data and COVID-19-associated mucormycosis: Time to pause and reassess?
作者信息
Nair Akshay Gopinathan
机构信息
Department of Ophthalmic Plastic Surgery and Ocular Oncology Services, Dr. Agarwal's Group of Hospitals, Mumbai, Maharashtra, India.
出版信息
Indian J Ophthalmol. 2022 Mar;70(3):1024-1025. doi: 10.4103/ijo.IJO_14_22.
Abstract
摘要
相似文献
1
Commentary: Data and COVID-19-associated mucormycosis: Time to pause and reassess?评论：数据与新型冠状病毒肺炎相关毛霉菌病：是时候暂停并重新评估了？
Indian J Ophthalmol. 2022 Mar;70(3):1024-1025. doi: 10.4103/ijo.IJO_14_22.
2
Commentary: COVID-19-associated mucormycosis: The ongoing battle.评论：新型冠状病毒肺炎相关毛霉菌病：持续的斗争
Indian J Ophthalmol. 2021 Dec;69(12):3683-3684. doi: 10.4103/ijo.IJO_2789_21.
3
Commentary on "Mucormycosis co-infection in the context of global COVID-19 outbreak: A fatal addition to the pandemic spectrum" (Int J Surg 2021, 92:106031) - A pulmonary perspective.关于《全球新冠疫情背景下的毛霉菌病合并感染：大流行谱中的致命新增情况》（《国际外科学杂志》2021年，第92卷：106031）的述评——肺部视角
Int J Surg. 2021 Oct;94:106116. doi: 10.1016/j.ijsu.2021.106116. Epub 2021 Sep 17.
4
Mucormycosis: An unanticipated progeny of COVID-19.毛霉菌病：COVID-19 的意外后果。
JNMA J Nepal Med Assoc. 2021 Sep 11;59(241):965-967. doi: 10.31729/jnma.6686.
5
Response to: COVID-19-associated mucormycosis and evolving evidence.回复：新型冠状病毒肺炎相关毛霉菌病及不断演变的证据
QJM. 2022 Jun 7;115(6):422. doi: 10.1093/qjmed/hcab191.
6
In-hospital prevalence of mucormycosis among coronavirus disease 2019 (COVID-19) patients and COVID-19 in mucormycosis: a systematic review and meta-analysis.2019冠状病毒病（COVID-19）患者中毛霉菌病的院内患病率及毛霉菌病中的COVID-19：一项系统评价和荟萃分析。
Int Forum Allergy Rhinol. 2022 Mar;12(3):313-317. doi: 10.1002/alr.22906. Epub 2021 Oct 11.
7
COVID-19 and Mucormycosis in India a Study on Implicated Risk Factors.印度的新冠病毒病与毛霉菌病：相关危险因素研究
J Assoc Physicians India. 2022 May;70(5):11-12.
8
Mucormycosis in COVID-19 recovered patients.新冠康复患者中的毛霉菌病
J Med Virol. 2022 Apr;94(4):1272-1273. doi: 10.1002/jmv.27522. Epub 2021 Dec 18.
9
[COVID-19 associated mucormycosis. A case in Argentina].[新型冠状病毒肺炎相关毛霉病。阿根廷的一例病例]
Medicina (B Aires). 2022;82(2):304-307.
10
Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.COVID-19 相关非糖尿病患者的鼻眶脑毛霉菌病。
R I Med J (2013). 2021 Oct 1;104(8):19-21.
引用本文的文献
1
Commentary: For every dark night, there is a brighter day.评论：每一个黑暗的夜晚过后，都会迎来更光明的白昼。
Indian J Ophthalmol. 2023 Feb;71(2):457. doi: 10.4103/ijo.IJO_9_23_9.
本文引用的文献
1
Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience.COVID-19 后发生的鼻眶脑毛霉病经皮眶后注射脂质体两性霉素 B 的转归：我们的经验。
Indian J Ophthalmol. 2022 Mar;70(3):1019-1024. doi: 10.4103/ijo.IJO_2356_21.
2
Incidence of Retinal Artery and Vein Occlusions During the COVID-19 Pandemic.新冠疫情期间视网膜动脉和静脉阻塞的发生率。
Ophthalmic Surg Lasers Imaging Retina. 2022 Jan;53(1):22-30. doi: 10.3928/23258160-20211209-01. Epub 2022 Jan 1.
3
Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review.经皮球后注射两性霉素B治疗鼻眶脑毛霉菌病的综述
Orbit. 2022 Jun;41(3):275-286. doi: 10.1080/01676830.2021.1990351. Epub 2021 Oct 31.
4
Magnetic resonance imaging in rhino-orbital-cerebral mucormycosis.鼻眶脑型毛霉菌病的磁共振成像
Indian J Ophthalmol. 2021 Jul;69(7):1915-1927. doi: 10.4103/ijo.IJO_1439_21.
5
Outcomes of a Modified Treatment Ladder Algorithm Using Retrobulbar Amphotericin B for Invasive Fungal Rhino-Orbital Sinusitis.使用球后注射两性霉素B治疗侵袭性真菌性鼻-眶-鼻窦炎的改良治疗阶梯算法的结果
Am J Ophthalmol. 2022 May;237:299-309. doi: 10.1016/j.ajo.2021.05.025. Epub 2021 Jun 9.
6
Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19.毛霉代码：2019冠状病毒病背景下鼻眶脑型毛霉病的诊断、分期和管理指南
Indian J Ophthalmol. 2021 Jun;69(6):1361-1365. doi: 10.4103/ijo.IJO_1165_21.
7
Simultaneous Bilateral Central Retinal Artery Occlusion following COVID-19 Infection.新冠病毒感染后并发双侧中央视网膜动脉阻塞。
Ocul Immunol Inflamm. 2021 May 19;29(4):671-674. doi: 10.1080/09273948.2021.1891262. Epub 2021 Apr 15.
Zotero 插件